Skip to main content
Equibles
FLNA logo

FLNA · Filana Therapeutics, Inc. · Metrics

Track FLNA — free

Use FLNA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research FLNA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.45 -0.03 (-7.07%) At close · Nov 12
Rebalance outlook locked
Market Cap
$22.52M
Shares
50.27M
Volume · Nov 12 432.53K Avg daily vol (3M) 2.01M

FLNA metrics

75 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.45
Market cap
$22.52M

Price action

23 metrics
Price change (1W)
-15.7%
Price change (30D)
-35.1%
Price change (3M)
-48.2%
Price change (6M)
-60.8%
Price change (YTD)
-75.7%
Price change (1Y)
-84.5%
Trailing year
Price change (5Y)
-99.3%
52-week high
$3.39
52-week low
$0.45
Change from 52-week high
-85.8%
Change from 52-week low
+6.9%
Annualized volatility
88.5%
Annualized volatility (3M)
119.7%
Implied volatility (30D)
128.1%
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
2.2
RSI (14D)
32.1
Price vs SMA 50
-33.9%
Price vs SMA 200
-62.7%
Avg volume (3M)
2.01M
Relative volume
0.1
Average dollar volume
$1.94M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
50.27M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
0.6×
reciprocal yield 169.7%
P / book
0.4
reciprocal yield 239.2%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-174.1%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-05-07

Profitability

9 metrics
Gross margin
—
Operating margin
76.3%
Trailing 12 months
Net margin
76.7%
Gross profit (TTM)
—
Operating profit (TTM)
−$45.39M
Net income (TTM)
−$42.20M
Trailing 12 months
Diluted EPS (TTM)
$-1.88
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.90
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-1.98
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-1.88
Operating cash flow per diluted share (TTM)
$-0.67
Free cash flow per diluted share (TTM)
$-0.68
Capital expenditures per diluted share (TTM)
$0.01
R&D per diluted share (TTM)
$0.55
Stock compensation per diluted share (TTM)
$0.41
Book value per share
$1.54

Growth

11 metrics
Revenue growth YoY
+1,328.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$41.12M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+0.7%
Year over year · more shares
Revenue CAGR (3Y)
+34.7%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-72.8%
Return on assets
-42.2%
Debt / equity
—
Current ratio
1.9
EBITDA (TTM)
−$12.72M
Free cash flow (TTM)
—
Quick ratio
1.9
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$46.99M
Latest balance sheet
Cash & equivalents
$46.99M
Total assets
$100.06M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$28.57M
Capital expenditures (TTM)
$553,000
R&D (TTM)
$15.57M
SG&A (TTM)
—
Stock compensation (TTM)
$16.99M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
87
13F filer change QoQ
-16
Institutional ownership
26.5%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
13.1%
Private-fund adviser ownership
10.4%
Active holders' share change QoQ
-18.5%
Holder tenure
8.3
Price vs estimated holder cost
-53.8%

Ownership (registered funds)

1 metrics
Index-fund ownership
5.7%

Short interest

3 metrics
Short interest
11.3%
Latest settlement · 20.6 days to cover
Days to cover
20.6d
Short-squeeze score
67 / 100

Insider activity

2 metrics
Net insider buying (90D)
$356,328
Insider-sentiment score
87 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1069530 CUSIP 14817C107 13F (30d) 73 filings 46 filers Visit website Investor relations